5438-70-0

Basic information

• Product Name: Ethyl 4-aminophenylacetate
• Synonyms: LABOTEST-BB LT01148116;H-APH(4)-OET;4-AMINOPHENYLACETIC ACID ETHYL ESTER;P-Aminophenyl Acetic Acid Ethyl Ester;Ethyl 4-aminophenylacetate, 98 %;4-Aminobenzeneacetic acid ethyl ester;Ethyl 4-aMinophenylacetate, 98% 1GR;2-(4-aminophenyl)acetic acid ethyl ester
• CAS NO: 5438-70-0
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.22
• EINECS: 202-303-5
• Product Categories: Aromatic Esters;Esters;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het;amine| carboxylic ester
• Mol File: 5438-70-0.mol

Chemical Properties

• Melting Point: 48-50 °C
• Boiling Point: 292.5 °C at 760 mmHg
• Flash Point: 149.4 °C
• Appearance: pinkish-white to beige powder
• Density: 1.112 g/cm³
• Vapor Pressure: 0.000589mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 4.55±0.10(Predicted)
• CAS DataBase Reference: Ethyl 4-aminophenylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-aminophenylacetate(5438-70-0)
• EPA Substance Registry System: Ethyl 4-aminophenylacetate(5438-70-0)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• Hazardous Substances Data: 5438-70-0(Hazardous Substances Data)

Usage

Chemical Properties

pinkish-white to beige powder

InChI:InChI=1/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3

Upstream product

• 64-17-5 ethanol 
• 1197-55-3 4-aminophenylacetic acid 
• 88975-34-2 ethyl 4-<(trifluoroacetyl)amino>benzeneacetate 
• 106-40-1 4-bromo-aniline 
• 123-30-8 4-amino-phenol 
• 13475-17-7 ethyl 2-(4-acetamidophenyl)acetate 
• 140-29-4 phenylacetonitrile 
• 104-03-0 4-nitrobenzeneacetic acid 
• 555-21-5 4-Nitrophenylacetonitrile 
• 105113-62-0 4-<(trifluoroacetyl)amino>benzeneacetic acid 
• 113180-63-5 4-<(trifluoroacetyl)amino>benzeneacetyl chloride 
• 83756-25-6 2-<4-(2,5-dimethylpyrrol-1-yl)benzilidene>-1,3-dithian 
• 95337-70-5 4-(2,5-dimethylpyrrol-1-yl)benzaldehyde 
• 26165-63-9 2-<4-(2,5-dimethylpyrrol-1-yl)phenyl>ethanoic acid 

Downstream Products

• 219313-75-4 {4-[bis-(2-hydroxy-ethyl)-amino]-phenyl}-acetic acid ethyl ester 
• 1197-55-3 4-aminophenylacetic acid 
• 62910-44-5 ethyl 4-(2-pentyloxy-5-chlorobenzamido)-phenylacetate 
• 62910-40-1 ethyl 4-(5-chloro-2-methoxybenzamido)-phenylacetate 
• 88975-57-9 [4-(3-Benzoyl-thioureido)-phenyl]-acetic acid ethyl ester 
• 88975-34-2 ethyl 4-<(trifluoroacetyl)amino>benzeneacetate 
• 224577-12-2 ethyl N-4-<<(benzyloxy)carbonyl>amino>phenylacetate 
• 253868-77-8 6-(4-Ethoxycarbonylmethylamino)-3-methyluracil 
• 265308-29-0 (diethoxy-phosphoryl)-(4-ethoxycarbonylmethyl-phenylamino)-acetic acid ethyl ester 
• 184041-87-0 N-(4-ethoxycarbonylmethyl-phenyl)-2,2-dimethyl-malonamic acid 
• 367255-29-6 4-hydrazinophenylacetic acid ethyl ester 
• 122063-99-4 ethyl (4-amino-3,5-dibromophenyl)acetate 

Relevant articles and documents

BIODERIVED EPOXIDE TRIAZINE NETWORKS AND METHODS OF MAKING THE SAME

The present disclosure relates to a method that includes a first reacting of a first molecule and formaldehyde and/or a paraformaldehyde to form a triazine-containing intermediate and a second reacting of the triazine-containing intermediate with a second

Chemoselective Hydrogenation of Nitroarenes Using an Air-Stable Base-Metal Catalyst

The reduction of nitroarenes to anilines as well as azobenzenes to hydrazobenzenes using a single base-metal catalyst is reported. The hydrogenation reactions are performed with an air-and moisture-stable manganese catalyst and proceed under relatively mild reaction conditions. The transformation tolerates a broad range of functional groups, affording aniline derivatives and hydrazobenzenes in high yields. Mechanistic studies suggest that the reaction proceeds via a bifunctional activation involving metal-ligand cooperative catalysis.

Hapten design and monoclonal antibody to fluoroacetamide, a small and highly toxic chemical

Fluoroacetamide (FAM) is a small (77 Da) and highly toxic chemical, formerly used as a rodenticide and potentially as a poison by terrorists. Poisoning with FAM has occurred in humans, but few reliably rapid detection methods and antidotes have been reported. Therefore, producing a specific antibody to FAM is not only critical for the development of a fast diagnostic but also a potential treatment. However, achieving this goal is a great challenge, mainly due to the very low molecular weight of FAM. Here, we design two groups of FAM haptens for the first time, maximally exposing the fluorine or amino groups, with the aid of linear aliphatic or phenyl-contained spacer arms. Interestingly, whereas the hapten with fluorine at the far end of the hapten did not induce an antibody response to FAM, the hapten with an amino group at the far end and phenyl-contained spacer arm triggered a significantly specific antibody response. Finally, a monoclonal antibody (mAb) named 5D11 was successfully obtained with an IC50 value of 97 μg mL?1 and negligible cross-reactivities to the other nine functional and structural analogs.

Benzo imidazo [2, 1-b] thiazole compound and application thereof (by machine translation)

The invention discloses a benzoimidazo [2, 1-b] thiazole compound and application thereof, and belongs to the technical field of medicines. The inhibitory activity of the synthesized benzimidazo [2, 1-b] thiazole analogues on FLTT3 is more than 90%, wherein the compounds (compounds 2 , 4, 6, 8 and 10) are IC of FLTT3-ITD kinase. 50 Lower value, in particular compound 2, IC IC50 The value is only 5.60 nm, and therefore the compound of the present invention may be used as an inhibitor FLTT3, or for preparing a drug capable of modulating or suppressing diseases associated with abnormal cell proliferation by affecting the enzymatic activity of one or more tyrosine kinases and interfering with aberrant cell proliferation, having a wide application prospect. (by machine translation)

Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors

As a class III receptor tyrosine kinase (RTK), FMS-like tyrosine kinase 3 (FLT3) is always overexpressed in many cases of acute leukemia. This paper studies the structure-based synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors. Encouragingly, compounds 15b, 16b, 24a, and 24c showed excellent biological activities in a low nanomolar range. In particular, compound 16b demonstrated significant inhibitory potency against FLT3-ITD (IC50 = 5.60 nM) and better antiproliferative activity than quizartinib against MV4-11 cell line (IC50 = 0.176 nM). It is indicated that compound 16b for the treatment of acute myeloid leukemia could be very promising.

Cobalt nanoparticles anchoring on nitrogen doped carbon with excellent performances for transfer hydrogenation of nitrocompounds to primary amines and N-substituted formamides with formic acid

Cobalt nanoparticles anchoring on nitrogen doped carbon derived from pyrolysis of a cobalt complex and chitosan were developed for reduction of nitrocompounds with neat formic acid to their corresponding amines or N-substituted formamides by switch of solvents. Characterization results revealed that most of the nitrogen atoms are present as graphitic N and pyridinic N as anchoring sites, and the cobalt nanoparticles are wrapped by nitrogen doped carbon layers, endowing the catalyst with excellent activity and superior reusability.

SYMMETRICAL TRIS-ARYL-AMIDE DERIVATIVES AND THEIR USE AS ANTI-HEPARANASE

The present invention relates to tris-aryl-amide derivatives having an anti-heparanase activity, in particular it relates to ureido/thioureido/ether tris-aryl-amide derivatives of formula The invention also relates to the use of such compounds as a medica

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

Rapid and Selective Cleavage of Amide Groups at Neutral pH: Applications from Hyaluronic Acid to Small Molecules

During our investigation to find suitable conditions to prepare very high molecular weight partially de-acetylated hyaluronic acid (HA), we discovered a powerful new method to cleave amide bonds using hydroxylamine salts at neutral pH with remarkable sele

Synthesis of androstene oxime-nitrogen mustard bioconjugates as potent antineoplastic agents

In the present study, synthesis and antineoplastic activity of phenylacetic acid and benzoic acid nitrogen mustard conjugates of various steroidal oximes are reported for the first time. The conjugation was achieved through a more stable oxime-ester linkage and the resulting newly synthesized conjugates were evaluated in vitro on various human cancer cell lines for cytotoxicity. The extent of their alkylating activity was investigated by the in vitro colorimetric 4-(p-nitrobenzyl)pyridine (NBP) assay. The 17E-steroidal oxime-benzoic acid mustard ester 3β-acetoxy-17E-[p-(N,N-bis(2-chloroethyl)amino)]benzoyloxyimino-androst-5-ene (8) emerged as the most potent conjugate having significant cytotoxicity on most of the NCI 60-cell lines. Outstanding growth inhibition was observed on the IGROV1 ovarian cancer cell line with GI50?=?0.937?μM. In general, the D-ring derived androstene oxime-nitrogen mustard conjugates were found to possess better antineoplastic activity over a variety of cancer cells in comparison to those derived from other rings of the steroid skeleton.